

December 12, 2023

TO: Saskatchewan Health Authority
Indigenous Services Canada - SK Region
Saskatchewan College of Respiratory Therapists
Saskatchewan College of Pharmacy Professionals
Saskatchewan Association of Licensed Practical Nurses
College of Physicians and Surgeons of Saskatchewan
Registered Psychiatric Nurses Association of Saskatchewan
Drug Plan and Extended Benefits Branch

Northern Intertribal Health Authority
Saskatchewan Medical Association
Saskatchewan College of Paramedics
College of Registered Nurses of Saskatchewan

Re: COVID-19 Program Updates:

- **Novavax Nuvaxovid™ XBB.1.5 Vaccine for 12+ Years**
- **XBB.1.5 COVID-19 Vaccination Schedules**

Dear Colleagues,

Health Canada authorized Novavax's Nuvaxovid™ XBB.1.5 vaccine on December 5, 2023. This vaccine will only be available at select public health centres for individuals 12 years of age and older who have a contraindication to or refuse to receive an mRNA XBB.1.5 COVID-19 vaccine. The required number of **Novavax Nuvaxovid XBB.1.5 vaccine doses is based on an individual's immunization history** (refer to **Appendix A Tables 1 and 2**).

- Upon receipt of Novavax XBB.1.5 vaccine, Public Health must discontinue the use of and discard all Novavax original monovalent vaccine stock and submit a wastage report.


The Saskatchewan Immunization Manual [Chapter 10](#) contains Novavax Nuvaxovid™ XBB.1.5 vaccine information, updated COVID-19 XBB.1.5 vaccine schedules (refer to **Appendix A**) and an updated Questions and Answers section. The Saskatchewan Immunization Manual [Chapter 10](#) will be posted as soon as possible.

- Note that in **Appendix A Tables 3 and 4, footnote #3** has been revised to align with recent updates in the [Canadian Immunization Guide's COVID-19 chapter](#) regarding the number of previous doses a child received before 5 years of age.

A revised [COVID-19 Contraindications and Precautions Background](#) document and Novavax Nuvaxovid™ XBB.1.5 administration document will be posted on the COVID-19 Immunization Manual website soon.

The Novavax Nuvaxovid™ XBB.1.5 fact sheet, after care sheet and screening questions will be posted as soon as possible at [COVID-19 Vaccine Details](#).

Sincerely,

A handwritten signature in black ink, appearing to read "J. Kryzanowski".

Dr. Julie Kryzanowski
Deputy Chief Medical Health Officer

cc: Medical Health Officers of Saskatchewan

Appendix A: XBB.1.5 COVID-19 Vaccination Schedules

***For a list of immunocompromising conditions, refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide: canada.ca/CIG - [COVID19 Immunocompromised](#)**

Table 1: Schedules for individuals presenting at 12 years and older who are **NOT immunocompromised**

Vaccination History (non-XBB.1.5)	XBB.1.5 Vaccine Dosage ²	XBB.1.5 doses required	Interval between last (non-XBB) dose and XBB.1.5 dose ¹
0 doses	Moderna = 0.5 ml (50 mcg)	1	6 months (min. 3 months)
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label)		
	Novavax 12+ = 0.5 ml (5 mcg)		
1 or more doses	Moderna = 0.5 ml (50 mcg)	1	6 months (min. 3 months)
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label)		
	Novavax 12+ = 0.5 ml (5 mcg)		

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required. For the purposes of vaccinating long term care facility, personal care home, or senior congregate living (i.e. assisted living facility) residents, XBB.1.5 vaccine can be administered less than 3 months after infection.

² The following dosages are considered invalid:

- Pfizer: 3 or 10 mcg administered at 12+ years of age.
- Moderna: 25 mcg administered at 12+ years of age.
- Administer an appropriate vaccine dosage based on age at presentation at a minimum interval of 4 weeks after an invalid (lower dosage for age) dose.

³ A 3-week (21 days) interval between doses 1 and 2 is acceptable, as per the Novavax XBB.1.5 product monograph.

Table 2: Schedules for individuals presenting at 12 years and older WHO ARE moderately to severely immunocompromised*

Vaccination History (non-XBB.1.5)	XBB.1.5 Vaccine Dosage ²	XBB.1.5 doses required	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	Moderna = 0.5 ml (50 mcg)	3	N/A	4-8 weeks ³
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label)			
	Novavax 12+ = 0.5 ml (5 mcg) ³			
1 dose	Moderna = 0.5 ml (50 mcg)	2	4-8 weeks	4-8 weeks ³
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label)			
	Novavax 12+ = 0.5 ml (5 mcg) ³			
2 doses	Moderna = 0.5 ml (50 mcg)	1	4-8 weeks	N/A
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label)			
	Novavax 12+ = 0.5 ml (5 mcg)			
3 or more doses	Moderna = 0.5 ml (50 mcg)	1	6 months (min. 3 months)	N/A
	Pfizer 12+ = 0.3 ml (30 mcg) (Grey cap/label);			
	Novavax 12+ = 0.5 ml (5 mcg)			

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required. For the purposes of vaccinating long term care facility, personal care home, or senior congregate living (i.e. assisted living facility) residents, XBB.1.5 vaccine can be administered less than 3 months after infection.

² The following dosages are considered invalid:

- Pfizer: 3 or 10 mcg administered at 12+ years of age.
- Moderna: 25 mcg administered at 12+ years of age.
- Administer an appropriate vaccine dosage based on age at presentation at a minimum interval of 4 weeks after an invalid (lower dosage for age) dose

³ A 3-week (21 days) interval between doses 1 and 2 is acceptable, as per the Novavax XBB.1.5 product monograph.

Table 3: mRNA Schedules for individuals presenting at 5-11 years who are NOT immunocompromised

Vaccination History (non-XBB.1.5)	XBB.1.5 Dosage ²	XBB.1.5 doses required	Interval between last dose and XBB.1.5 dose ¹
0 or more doses	Moderna = 0.25 ml (25 mcg)	1 ³	6 months (min. 3 months)
	Pfizer 5-11 = 0.3 ml (10 mcg) (blue cap/label ; DO NOT DILUTE)		

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.

² The following dosages are considered invalid:

- Pfizer: 3 mcg administered at 5-11 years of age.
- Administer an appropriate vaccine dosage based on age at presentation at a minimum interval of 4 weeks after an invalid (lower dosage for age) dose.

³ Children who started their primary series with 2 doses of a non-XBB.1.5 Pfizer vaccine when they were less than 5 years of age and are completing their primary series at 5 years or older, are recommended to receive a total of 3 doses in their primary series.

Table 4: mRNA Schedule for individuals presenting at 5 to 11 years WHO ARE moderately to severely immunocompromised*

Vaccination History (non-XBB.1.5)	XBB.1.5 Dosage ²	XBB.1.5 doses required ³	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	Moderna = 0.25 ml (25 mcg)	3	N/A	4-8 weeks
	Pfizer 5-11= 0.3 ml (10 mcg) (blue cap/label ; DO NOT DILUTE)			
1 dose	Moderna = 0.25 ml (25 mcg)	2	4-8 weeks	4-8 weeks
	Pfizer 5-11= 0.3 ml (10 mcg) (blue cap/label ; DO NOT DILUTE)			
2 doses	Moderna = 0.25 ml (25 mcg)	1 ³	4-8 weeks	4-8 weeks ³
	Pfizer 5-11 = 0.3 ml (10 mcg) (blue cap/label ; DO NOT DILUTE)			
3 or more doses	Moderna= 0.25 ml (25 mcg)	1	6 months (min. 3 months)	N/A
	Pfizer 5-11 = 0.3 ml (10 mcg) (blue cap/label ; DO NOT DILUTE)			

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.

² The following dosages are considered invalid:

- Pfizer: 3 mcg administered at 5-11 years of age.
- Administer an appropriate vaccine dosage based on age at presentation at a minimum interval of 4 weeks after an invalid (lower dosage for age) dose.

³ Children who are moderately to severely immunocompromised and started their primary series with 2 or 3 doses of a non-XBB.1.5 Pfizer vaccine when they were less than 5 years of age and are completing their primary series at 5 years of age or older, are recommended to receive a total of 4 doses of COVID-19 vaccine in their primary series.

Table 5: MODERNA SPIKEVAX™ XBB.1.5 schedules for children presenting at age 6 months to 4 years who are **NOT immunocompromised**

Vaccination History (non XBB.1.5)	Moderna XBB.1.5 6 mo-4 yr Dosage	Number of doses required ²	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	0.25 ml (25 mcg)	2	N/A	4-8 weeks
1 dose Pfizer	0.25 ml (25 mcg)	2	4-8 weeks	4-8 weeks
2 doses Pfizer	0.25 ml (25 mcg)	1	4-8 weeks	N/A
1 dose Pfizer and 1 dose Moderna				
1 dose Moderna				
3 doses Pfizer	0.25 ml (25 mcg)	1	6 months (min. 3 months)	N/A
2 doses Moderna				
2 doses Pfizer and 1 dose Moderna				
1 dose Pfizer and 2 doses Moderna				

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.

² For mixed schedules consisting of at least one dose of Pfizer 3 mcg, 3 doses are recommended as per the Pfizer XBB.1.5 schedule in **Table 6**. Either Pfizer or Moderna can be used to complete the remaining doses.

Table 6: PFIZER COMIRNATY® XBB.1.5 schedules for children presenting at age 6 months to 4 years who are **NOT immunocompromised**

Vaccination History (non-XBB.1.5)	Pfizer 6mo-4yr XBB.1.5 Dosage (Maroon cap/label) DILUTE PRIOR TO USE	Number of doses required	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	0.2 ml (3 mcg)	3	N/A	4-8 weeks
1 dose Pfizer	0.2 ml (3 mcg)	2	4-8 weeks	4-8 weeks
1 dose Moderna				
2 doses Pfizer	0.2 ml (3 mcg)	1	4-8 weeks	N/A
1 dose Pfizer and 1 dose Moderna				
3 doses Pfizer				
2 doses Moderna	0.2 ml (3 mcg)	1	6 months (min. 3 months)	N/A
2 doses Pfizer and 1 dose Moderna				
1 dose Pfizer and 2 doses Moderna				

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.

Table 7: MODERNA SPIKEVAX™ XBB.1.5 schedules for children presenting at age 6 months to 4 years WHO ARE moderately to severely immunocompromised*

Vaccination History (non-XBB.1.5)	Moderna XBB.1.5 6 mo-4 yr Dosage	Number of doses required ²	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	0.25 ml (25 mcg)	3	N/A	4-8 weeks
1 dose Pfizer	0.25 ml (25 mcg)	3	4-8 weeks	4-8 weeks
1 dose Moderna	0.25 ml (25 mcg)	2	4-8 weeks	4-8 weeks
2 doses Pfizer				
1 dose Pfizer and 1 dose Moderna				
2 doses Moderna	0.25 ml (25 mcg)	1	4-8 weeks	N/A
3 doses Pfizer				
2 doses Pfizer and 1 dose Moderna				
1 dose Pfizer and 2 doses Moderna	0.25 ml (25 mcg)	1	6 months (min. 3 months)	N/A
4 doses Pfizer				
3 doses Moderna				
3 doses Pfizer and 1 dose Moderna				
2 doses of Pfizer and 2 doses of Moderna				
1 dose of Pfizer and 3 doses of Moderna				

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.

² For mixed schedules consisting of at least one dose of Pfizer 3 mcg, 4 total doses are recommended as per the Pfizer Comirnaty XBB.1.5 schedule in **Table 8**. Either Pfizer or Moderna can be used to complete the remaining doses.

Table 8: PFIZER COMIRNATY® XBB.1.5 schedules for children presenting at age 6 months to 4 years WHO ARE moderately to severely immunocompromised*

Vaccination History (non-XBB.1.5)	Pfizer 6 mo -4 yr XBB.1.5 Dosage (Maroon cap /label) DILUTE PRIOR TO USE	Number of doses	Interval between last dose and first XBB.1.5 dose ¹	Interval between XBB.1.5 doses ¹
0 doses	0.2 ml (3 mcg)	4	N/A	4-8 weeks
1 dose Pfizer	0.2 ml (3 mcg)	3	4-8 weeks	4-8 weeks
1 dose Moderna				
2 doses Moderna	0.2 ml (3 mcg)	2	4-8 weeks	N/A
2 doses Pfizer				
1 dose Pfizer and 1 dose Moderna				
3 doses Pfizer				
2 doses Pfizer and 1 dose Moderna	0.2 ml (3 mcg)	1	4-8 weeks	N/A
1 dose Pfizer and 2 doses Moderna				
4 doses Pfizer	0.2 ml (3 mcg)	1	6 months (min. 3 months)	N/A
3 doses Moderna				
3 doses Pfizer and 1 dose Moderna				
2 doses of Pfizer and 2 doses of Moderna				
1 dose of Pfizer and 3 doses of Moderna				

¹ For those who had previous SARS-CoV-2 infection, an interval of 6 months (min. 3 months) is required.